William Blair Issues Negative Estimate for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Analysts at William Blair cut their Q1 2025 earnings estimates for Arcturus Therapeutics in a research report issued on Thursday, March 13th. William Blair analyst M. Minter now expects that the biotechnology company will post earnings per share of ($1.39) for the quarter, down from their prior forecast of ($0.53). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. HC Wainwright dropped their target price on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Finally, BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Stock Down 3.0 %

NASDAQ:ARCT opened at $13.73 on Monday. Arcturus Therapeutics has a 12 month low of $12.75 and a 12 month high of $45.00. The firm has a market cap of $372.36 million, a price-to-earnings ratio of -6.18 and a beta of 2.96. The company’s 50 day moving average is $16.40 and its 200-day moving average is $18.19.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARCT. Balyasny Asset Management L.P. bought a new stake in Arcturus Therapeutics in the 4th quarter valued at $9,312,000. Schonfeld Strategic Advisors LLC increased its holdings in Arcturus Therapeutics by 129.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock valued at $14,409,000 after buying an additional 479,482 shares during the period. J. Goldman & Co LP acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at $5,024,000. MPM Bioimpact LLC boosted its stake in shares of Arcturus Therapeutics by 109.5% in the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company’s stock valued at $7,805,000 after purchasing an additional 240,435 shares in the last quarter. Finally, Empire Life Investments Inc. boosted its stake in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after purchasing an additional 128,771 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.